JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
Volume 310, Issue 3, Pages G155-G162
Publisher
American Physiological Society
Online
2015-11-26
DOI
10.1152/ajpgi.00311.2015
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
- (2015) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
- (2014) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases
- (2014) Silvio Danese et al. GASTROENTEROLOGY
- Update on Janus Kinase Antagonists in Inflammatory Bowel Disease
- (2014) Brigid S. Boland et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
- (2014) J. Wollenhaupt et al. JOURNAL OF RHEUMATOLOGY
- Tofacitinib versus Methotrexate in Rheumatoid Arthritis
- (2014) Eun Bong Lee et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inflammatory bowel disease: Pathogenesis
- (2014) Yi-Zhen Zhang WORLD JOURNAL OF GASTROENTEROLOGY
- Inflammatory pathways of importance for management of inflammatory bowel disease
- (2014) Jannie Pedersen WORLD JOURNAL OF GASTROENTEROLOGY
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- (2013) Joel Kremer et al. ANNALS OF INTERNAL MEDICINE
- Tabalumab in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate and Naive to Biologic Therapy: A Phase II, Randomized, Placebo-Controlled Trial
- (2013) M. C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Innate and adaptive immunity in inflammatory bowel disease
- (2013) Alessandra Geremia et al. AUTOIMMUNITY REVIEWS
- Biologic therapy for autoimmune diseases: an update
- (2013) Ziv Rosman et al. BMC Medicine
- A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
- (2013) W.C. Ports et al. BRITISH JOURNAL OF DERMATOLOGY
- The role of IL-15 in gastrointestinal diseases: A bridge between innate and adaptive immune response
- (2013) Danilo Pagliari et al. CYTOKINE & GROWTH FACTOR REVIEWS
- American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti–TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease
- (2013) Jonathan P. Terdiman et al. GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- New targets for mucosal healing and therapy in inflammatory bowel diseases
- (2013) M F Neurath Mucosal Immunology
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Mucosal healing in inflammatory bowel diseases: a systematic review
- (2012) Markus F Neurath et al. GUT
- Whatʼs the next best cytokine target in IBD?
- (2012) Thomas T. MacDonald et al. INFLAMMATORY BOWEL DISEASES
- Ulcerative colitis
- (2012) Ingrid Ordás et al. LANCET
- Crohn's disease
- (2012) Daniel C Baumgart et al. LANCET
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review article: remission rates achievable by current therapies for inflammatory bowel disease
- (2011) L. Peyrin-Biroulet et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Does Anti-TNF Therapy Reduce the Requirement for Surgery in Ulcerative Colitis? A Systematic Review
- (2011) Jerome Filippi et al. CURRENT DRUG TARGETS
- Proinflammatory Cytokines in the Pathogenesis of Inflammatory Bowel Diseases
- (2011) Warren Strober et al. GASTROENTEROLOGY
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- Intestinal homeostasis and its breakdown in inflammatory bowel disease
- (2011) Kevin J. Maloy et al. NATURE
- Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
- (2010) Asher Kornbluth et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
- (2010) Debra M Meyer et al. Journal of Inflammation-London
- Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection
- (2010) Mark E. Flanagan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis
- (2009) J. P. GISBERT et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Management of Crohn's Disease in Adults
- (2009) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy
- (2009) Emőke Rácz et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Late Developmental Plasticity in the T Helper 17 Lineage
- (2009) Yun Kyung Lee et al. IMMUNITY
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Clinical implications of mucosal healing for the management of IBD
- (2009) Guillaume Pineton de Chambrun et al. Nature Reviews Gastroenterology & Hepatology
- Inflammatory Bowel Disease
- (2009) Clara Abraham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intracellular signal pathways: Potential for therapies
- (2009) Melissa Mavers et al. Current Rheumatology Reports
- Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
- (2008) Laurent Peyrin–Biroulet et al. Clinical Gastroenterology and Hepatology
- Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
- (2008) F Schnitzler et al. GUT
- Therapeutic targeting of Janus kinases
- (2008) Marko Pesu et al. IMMUNOLOGICAL REVIEWS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started